Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This double-blind, randomized, two-cohort, placebo-controlled, parallel group study
characterized the pharmacokinetics, safety, and tolerability of MNTX following single doses
and at steady-state during multiple dosing and assessed the effects of aging on the
pharmacokinetics, safety and tolerability of MNTX.
Phase:
Phase 1
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.